Therapeutic vitamin D conjugates

• US 10,702,574 B2
• Filed: 02/11/2017
• Issued: 07/07/2020
• Est. Priority Date: 10/22/2014
• Status: Active Grant

• Current Assignee: Extend Biosciences, Inc.
• Original Assignee: Extend Biosciences, Inc.
• Inventors: Soliman, Tarik, Hales, Laura M., Hall, Daniel B., So, Christopher, Sard, Howard P., Hegde, Vishnumurthy
• Primary Examiner(s): Alstrum-Acevedo, James H
• Assistant Examiner(s): Martinez, Tara L
• Application Number:
  US15/430,449
• Publication Number:
  US 20170216449A1
• Time in Patent Office: 1,242 Days
• Field of Search: None
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 47/551 one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

Claims

1. A carrier-drug conjugate comprising a targeting group that is a vitamin D that is not hydroxylated at the carbon 1, conjugated to a therapeutic peptide at the carbon 3 position of said vitamin D targeting group position via a scaffold, wherein said carrier increases the absorption, bioavailability, or half-life of said therapeutic peptide in circulation when compared to a non-conjugated form of said therapeutic peptide.

2. The carrier-drug conjugate of claim 1, wherein said targeting group is conjugated to said therapeutic peptide via a scaffold that is selected from the group consisting of poly(ethylene glycol), polylysine, polyethyleneimine, poly(propyleneglycol), a peptide, an amino acid, a nucleic acid, a glycan, a modifying group that contains a reactive linker, a water-soluble polymer, a small carbon chain linker, and an additional therapeutic peptide.

12. The carrier-drug conjugate of claim 1, wherein said vitamin D is hydroxylated at the carbon 25 position.

3. A pharmaceutical composition comprising a carrier-drug conjugate comprising a targeting group that is a vitamin D that is not hydroxylated at the carbon 1 position, conjugated to a therapeutic peptide at the carbon 3 position of said vitamin D targeting group via a scaffold.

4. The pharmaceutical composition of claim 3, wherein said carrier increases the absorption, bioavailability, or half-life of said therapeutic peptide in circulation when compared to a non-conjugated form of said therapeutic peptide.

5. The pharmaceutical composition of claim 4 wherein said scaffold is selected from the group consisting of poly(ethylene glycol), polylysine, polyethyleneimine, poly(propyleneglycol), a peptide, an amino acid, a nucleic acid, a glycan, a modifying group that contains a reactive linker, a water-soluble polymer, a small carbon chain linker, and an additional therapeutic compound.

6. The pharmaceutical composition of claim 3, wherein said therapeutic peptide has ghrelin activity and comprises an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:

4.

7. The pharmaceutical composition of claim 3, wherein said therapeutic peptide has the amino acid sequence of SEQ ID NO:

2.

8. The pharmaceutical composition of claim 3, wherein said therapeutic peptide has the amino acid sequence of SEQ ID NO:

3.

9. The pharmaceutical composition of claim 3, wherein said therapeutic peptide has the amino acid sequence of SEQ ID NO:

4.

10. The pharmaceutical composition of claim 3, wherein said therapeutic peptide has the amino acid sequence of SEQ ID NO:

5.

11. The pharmaceutical composition of claim 3, wherein said scaffold is poly(ethylene glycol).

13. A method of treating a patient with a conjugated therapeutic peptide that has an increased absorption, bioavailability or circulating half-life when compared to a non-conjugated form of said therapeutic peptide, comprising administering an effective amount of the pharmaceutical composition of claim 3.

14. The method of claim 13, wherein said therapeutic peptide has ghrelin activity and comprises an amino acid sequence with at least a 90% sequence identity to a protein of SEQ ID NO:

4.

15. The method of claim 14, wherein said therapeutic peptide comprises the amino acid sequence of SEQ ID NO:

2.

16. The method of claim 14, wherein said therapeutic peptide comprises the amino acid sequence of SEQ ID NO:

3.

17. The method of claim 14, wherein said therapeutic peptide comprises the amino acid sequence of SEQ ID NO:

4.

18. The method of claim 14, wherein said therapeutic peptide comprises the amino acid sequence of SEQ ID NO:

5.

19. The method of claim 14, comprising a scaffold that is poly(ethylene glycol).

20. The method of claim 13, comprising a scaffold that is poly(ethylene glycol).

21. The method of claim 13, wherein said pharmaceutical composition is delivered to said patient by a transdermal, oral, parenteral, subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial injection, infusion, inhalation, ocular, topical, rectal, nasal, buccal, sublingual, vaginal, or implanted reservoir mode.

22. A method of manufacturing the pharmaceutical composition of claim 3, comprising conjugating said targeting group and said therapeutic peptide, wherein said conjugating step utilizes a coupling group.

23. The method according to claim 22, wherein said coupling group is selected from the group consisting of an amine-reactive group, a thiol-reactive group, a maleimide group, a thiol group, an aldehyde group, an NETS-ester group, a haloacetyl group, an iodoacetyl group, a bromoacetyl groups, a SMCC group, a sulfo SMCC group, a carbodiimide group, bifunctional cross-linkers, NHS-maleimido, and combinations thereof.

24. The pharmaceutical composition resulting from manufacturing the pharmaceutical composition of claim 3, comprising conjugating said targeting group and said therapeutic peptide, wherein said conjugating step utilizes a coupling group, wherein said composition comprises a carrier-drug compound containing a linkage selected from the group consisting of a thiol linkage, an amide linkage, an oxime linkage, a hydrazone linkage, and a thiazolidinone linkage.

25. The method according to claim 22, wherein said conjugating step is accomplished by cycloaddition reactions.

26. The method according to claim 25, wherein said cycloaddition reactions incorporates click chemistry.

27. A pharmaceutical carrier comprising a formula I:

B-(L)^a-S-(M)^b-C 

 

I

Wherein;

B is a targeting group that is a vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position to (L)^a;

S is a scaffold moiety, comprising poly(ethylene glycol), polylysine, polyethyleneimine, poly(propyleneglycol), a peptide, an amino acid, a nucleic acid, a glycan, a modifying group that contains a reactive linker, polylactic acid, a water-soluble polymer, a small carbon chain linker, or an additional therapeutic moiety;

C is an amine-reactive group, a thiol-reactive group, a maleimide group, a thiol group, a disulfide group, an aldehyde group, an NETS-ester group, a 4-nitrophenyl ester, an acylimidazole, a haloacetyl group, an iodoacetyl group, a bromoacetyl groups, a SMCC group, a sulfo SMCC group, a carbodiimide group and bifunctional cross-linkers such as NHS-Maleimido or combinations thereof;

(L)^a and (M)^b are linkers independently selected from (CH₂)_n—

, —

C(O)NH—

, —

HNC(O)—

, —

C(O)O—

, —

OC(O)—

, —

O—

, —

S—

S—

, —

S—

, —

S(O)—

, —

S(O)₂— and

—

NH—

;

a is an integer from 0-4;

b is an integer from 0-4; and

n is an integer from 0-3.

28. The pharmaceutical carrier of claim 27 comprising formula V:

29. The pharmaceutical carrier of claim 27 comprising formula VI:

30. The pharmaceutical carrier of claim 27 comprising formula VII:

31. A pharmaceutical composition, comprising:

a) a therapeutic peptide,

b) a stably attached scaffold,

c) a targeting group that is a vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position,

wherein after administration to a first test subject, said therapeutic peptide has a half life measured by Enzyme Linked Immunosorbant Assay (ELISA) analysis of blood samples taken at a plurality of time points that is greater than a half life of said therapeutic peptide administered to a second test subject without said stably attached scaffold moiety and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points.

32. The pharmaceutical composition of claim 31, wherein said administration to said first and second subjects is accomplished by subcutaneous injection.

33. The pharmaceutical composition of claim 31, wherein said therapeutic peptide stably attached to said scaffold and targeting group retains substantially the same activity as said therapeutic peptide not stably attached to said scaffold and targeting group as measured by a functional assay.

34. The pharmaceutical composition of claim 33, wherein a scaffold mass range is selected from the group consisting of 100 Da. to 20,000 Da., 200 Da. to 15,000 Da., 300 Da. to 10,000 Da., 400 Da. to 9,000 Da., 500 Da. to 5,000 Da., 600 Da. to 2,000 Da., 1000 Da. to 200,000 Da., 20.00 Da. to 200,000 Da., 100,000 to 200,000 Da., 5000 Da. to 100,000 Da., 10,000 Da. to 80,000 Da., 20,000 Da. to 60,000 Da., and 20,000 Da. to 40,000 Da.

35. The pharmaceutical composition of claim 33, wherein said scaffold is approximately the same mass as the therapeutic protein.

36. A carrier-drug conjugate comprising a targeting group that is vitamin D, not hydroxylated at the carbon 1, non-releasably conjugated at the carbon 3 position via a scaffold to a therapeutic peptide, wherein said carrier increases the absorption, bioavailability, or half-life of said therapeutic peptide in circulation when compared to a non-conjugated form of said therapeutic peptide.

37. The carrier-drug conjugate of claim 36, wherein said vitamin D is a secosteroid and is non-hormonal.

38. The carrier-drug conjugate of claim 36, wherein said therapeutic peptide retains substantially the same activity as said therapeutic peptide not conjugated to said targeting group as measured by a functional assay.

39. The carrier-drug conjugate of claim 38, wherein said targeting group is conjugated to said therapeutic peptide via a scaffold that is selected from the group consisting of poly(ethylene glycol), polylysine, polyethyleneimine, poly(propyleneglycol), a peptide, an amino acid, a nucleic acid, a glycan, a modifying group that contains a reactive linker, a water-soluble polymer, a small carbon chain linker, and an additional therapeutic compound.

40. The carrier-drug conjugate of claim 39, wherein said scaffold is approximately the same mass as the therapeutic peptide.